Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab.

ABSTRACT: Nivolumab plus ipilimumab (aCTLA-4/aPD-1) combination therapy has significantly improved clinical outcomes in patients with metastatic melanoma, with 50%-60% of patients responding to treatment, but predictors of response are poorly characterized. We hypothesized that circulating cytokines and peripheral white blood cells may predict response to therapy and evaluated 15 cytokines and complete blood counts (CBC with differentials) from 89 patients with advanced melanoma treated with combination therapy from three points in time: pre-treatment, one month and approximately three months after starting therapy. Clinical endpoints evaluated included durable clinical benefit (DCB), progression-free survival (PFS), and overall survival (OS). A parsimonious predictive model was developed to identif

SUBMITTER: Chen J 

PROVIDER: S-EPMC11660408 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature